Advertisement
News
Advertisement

MAKO Surgical Corp. Showcases MAKOplasty@ Total Hip Arthroplasty at American Academy of Orthopaedic Surgeons 2012 Annual Meeting

Wed, 02/08/2012 - 3:45am
The Associated Press

/FROM PR NEWSWIRE DALLAS 888-776-3971/

STK NASDAQ-NMS:MAKO

IN HEA MTC MEQ SPM

SU TDS

TO BUSINESS, HEALTH, AND MEDICAL EDITORS:

MAKO Surgical Corp. Showcases MAKOplasty@ Total Hip Arthroplasty at

American Academy of Orthopaedic Surgeons 2012 Annual Meeting

SAN FRANCISCO, Feb. 8, 2012 /PRNewswire/ -- MAKO Surgical Corp.

(NASDAQ: MAKO), a leader in robotic arm assisted partial knee

arthroplasty worldwide, today announced the MAKOplasty@ Total Hip

Arthroplasty (THA) application will be featured at the American

Academy of Orthopaedic Surgeons 2012 Annual Meeting (AAOS) being held

on February 7-11, 2012 at the Moscone Center in San Francisco,

California.

MAKOplasty@ THA is the newest application for MAKO's RIO@ Robotic Arm

Interactive Orthopedic System. The RIO@ system will be on exhibit at

MAKO's AAOS Annual Meeting Booth ?2353. During the meeting,

experienced MAKOplasty@ orthopedic surgeons will give presentations

and hands-on demonstrations of the MAKOplasty@ THA application.

"There is clearly a need for precision and accuracy in total hip

replacement. We believe the RIO@ system, which enables surgeons to

achieve consistently reproducible precision for the individual

patient, along with our MAKOplasty@ THA, are key drivers in leading

our growing presence in orthopedic surgery," said Maurice R. Ferre,

M.D., president and CEO of MAKO.

MAKOplasty@ THA builds upon MAKOplasty@ Partial Knee Resurfacing's

proven benefits for patients with early to mid-stage osteoarthritis of

the knee. To date, nearly 13,000 patients have benefited from

MAKOplasty@ partial knee and total hip procedures. In 2012, MAKO

anticipates to perform 11,000 to 13,000 MAKOplasty@ procedures.

MAKOplasty@ THA was introduced in 2011 and is designed to support a

surgeon's ability to more accurately align and position a hip implant

relative to the specific needs of a patient. It provides a surgeon

with a pre-operative 3-D reconstruction of a patient's hip that is

used to develop a patient-specific surgical plan. The surgeon then

uses the RIO@ robotic arm during the procedure to prepare the joint

and optimally place the hip implant to the plan.

As of December 31, 2011, 49 MAKOplasty@ THA applications have been

sold in the U.S.; hospitals in California, New York, and Florida are

among many locations nationwide now offering MAKOplasty@ THA.

More information about MAKOplasty@ can be found at

http://makoplasty.com.

About MAKO Surgical Corp. MAKO Surgical Corp. is a medical device

company that markets its RIO@ Robotic-Arm Interactive Orthopedic

system, joint specific applications for the knee and hip, and

proprietary RESTORIS@ implants for orthopedic procedures called

MAKOplasty@. The RIO is a surgeon-interactive tactile surgical

platform that incorporates a robotic arm and patient-specific

visualization technology, which enables precise, consistently

reproducible bone resection for the accurate insertion and alignment

of MAKO's RESTORIS implants. The MAKOplasty solution incorporates

technologies enabled by an intellectual property portfolio including

more than 300 U.S. and foreign, owned and licensed, patents and patent

applications. Additional information can be found at

www.makosurgical.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding,

among other things, statements related to expectations, goals, plans,

objectives and future events. MAKO intends such forward-looking

statements to be covered by the safe harbor provisions for

forward-looking statements contained in Section 21E of the Securities

Exchange Act of 1934 and the Private Securities Reform Act of 1995. In

some cases, forward-looking statements can be identified by the

following words: "may," "will," "could," "would," "should," "expect,"

"intend," "plan," "anticipate," "believe," "estimate," "predict,"

"project," "potential," "continue," "ongoing," "guidance" or the

negative of these terms or other comparable terminology, although not

all forward-looking statements contain these words. Examples of such

statements include, but are not limited to, statements about the

nature, timing and number of planned new product introductions; market

acceptance of MAKOplasty, including the RIO system, and MAKO RESTORIS@

family of implant systems; the future availability from third-party

suppliers, including single source suppliers, of implants for and

components of the RIO system; the anticipated adequacy of our capital

resources to meet the needs of MAKO's business; MAKO's ability to

sustain, and MAKO's goals for, sales and earnings growth including

projections regarding systems installations; and MAKO's success in

achieving timely approval or clearance of products with domestic and

foreign regulatory entities. These statements are based on the current

estimates and assumptions of our management as of the date of this

press release and are subject to risks, uncertainties, changes in

circumstances, assumptions and other factors that may cause actual

results to differ materially from those indicated by forward-looking

statements, many of which are beyond MAKO's ability to control or

predict. Such factors, among others, may have a material adverse

effect on MAKO's business, financial condition and results of

operations and may include the potentially significant impact of a

continued economic downturn or delayed economic recovery on the

ability of MAKO's customers to secure adequate funding, including

access to credit, for the purchase of MAKO's products or cause MAKO's

customers to delay a purchasing decision, changes in competitive

conditions and prices in MAKO's markets, unanticipated issues relating

to intended product launches, decreases in sales of MAKO's principal

product lines, decreases in utilization of MAKO's principal product

line or in procedure volume, increases in expenditures related to

increased or changing governmental regulation or taxation of MAKO's

business, both nationally and internationally, unanticipated issues in

complying with domestic or foreign regulatory requirements related to

MAKO's current products or securing regulatory clearance or approvals

for new products or upgrades or changes to MAKO's current products,

the impact of the recently enacted United States healthcare reform

legislation on hospital spending, reimbursement, and the taxing of

medical device companies, the potential impact of the informal

Securities and Exchange Commission inquiry and the findings of that

inquiry, loss of key management and other personnel or inability to

attract such management and other personnel and unanticipated

intellectual property expenditures required to develop, market, and

defend MAKO's products. These and other risks are described in greater

detail under Item 1A, "Risk Factors," in MAKO's periodic filings with

the Securities and Exchange Commission, including MAKO's annual report

on Form 10-K for the year ended December 31, 2010 filed on March 10,

2011 and quarterly report on Form 10-Q for the quarter ended September

30, 2011 filed on November 9, 2011. Given these uncertainties, undue

reliance should not be placed on these forward-looking statements.

MAKO does not undertake any obligation to release any revisions to

these forward-looking statements publicly to reflect events or

circumstances after the date of this press release or to reflect the

occurrence of unanticipated events.

"MAKOplasty@," "RESTORIS@," "RIO@," as well as the "MAKO" logo,

whether standing alone or in connection with the words "MAKO Surgical

Corp." are trademarks of MAKO Surgical Corp.

SOURCE MAKO Surgical Corp.

-0- 02/08/2012

/CONTACT: Media, Yvette Cuello, MAKO Surgical Corp., +1-954-628-0432 (o), +1-954-609-5085 (m), mcuello@makosurgical.com; or Cynthia Kalb, MAKO Surgical Corp., +1-954-628-0426 (o), +1-954-218-9133 (m), ckalb@makosurgical.com; or Lily Eng, Weber Shandwick, +1-415-262-5966, leng@webershandwick.com; or Investors, Susan Verde, MAKO Surgical Corp., +1-954-628-1706, investorrelations@makosurgical.com; or Mark Klausner, Westwicke Partners, +1-443-213-0500, makosurgical@westwicke.com

/Web Site: http://www.makosurgical.com

http://makoplasty.com

(NASDAQ-NMS:MAKO) /

CO: MAKO Surgical Corp.

ST: California

IN: HEA MTC MEQ SPM

SU: TDS

PRN

-- SF49574 --

0000 02/08/2012 13:00:00 EDT http://www.prnewswire.com

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading